113 related articles for article (PubMed ID: 7894125)
1. [Taxol (paclitaxel), first molecule of a new class of cytotoxic agents: taxanes].
Chazard M; Pellae-Cosset B; Garet F; Soares JA; Lucidi B; Lavail Y; Lenaz L
Bull Cancer; 1994 Mar; 81(3):173-81. PubMed ID: 7894125
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of Taxol.
Arbuck SG; Christian MC; Fisherman JS; Cazenave LA; Sarosy G; Suffness M; Adams J; Canetta R; Cole KE; Friedman MA
J Natl Cancer Inst Monogr; 1993; (15):11-24. PubMed ID: 7912517
[TBL] [Abstract][Full Text] [Related]
3. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
Yamazaki S; Sekine I; Saijo N
Gan To Kagaku Ryoho; 1998 Mar; 25(4):605-15. PubMed ID: 9530372
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
Hájek R; Vorlicek J; Slavik M
Neoplasma; 1996; 43(3):141-54. PubMed ID: 8841500
[TBL] [Abstract][Full Text] [Related]
5. [Paclitaxel (Taxol)].
Hájek R
Cas Lek Cesk; 1996 Jun; 135(12):393-6. PubMed ID: 8706079
[TBL] [Abstract][Full Text] [Related]
6. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Luck HJ; Thomssen C; duBois A; Lisboa BW; Untch M; Kuhnle H; Konecny G; Janicke F; Meerpohl HG; Lindner C; Hecker D; Diergarten K
Semin Oncol; 1996 Feb; 23(1 Suppl 1):33-6. PubMed ID: 8629034
[TBL] [Abstract][Full Text] [Related]
7. The mode of action of taxol: apoptosis at low concentration and necrosis at high concentration.
Yeung TK; Germond C; Chen X; Wang Z
Biochem Biophys Res Commun; 1999 Sep; 263(2):398-404. PubMed ID: 10491305
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological action of paclitaxel].
Potemski P; Płuzańska A
Pol Merkur Lekarski; 1999 Jan; 6(31):27-9. PubMed ID: 10344150
[TBL] [Abstract][Full Text] [Related]
10. New anticancer agents: taxol, camptothecin analogs, and anthrapyrazoles.
Hawkins MJ
Oncology (Williston Park); 1992 Dec; 6(12):17-23; discussion 27-30. PubMed ID: 1361358
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials referral resource. Clinical trials with taxol.
Cheson BD
Oncology (Williston Park); 1992 Mar; 6(3):67-70. PubMed ID: 1348954
[No Abstract] [Full Text] [Related]
12. [A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].
Wu H; Guan Z; Lin T
Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):148-52. PubMed ID: 10920970
[TBL] [Abstract][Full Text] [Related]
13. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents.
Mooberry SL; Tien G; Hernandez AH; Plubrukarn A; Davidson BS
Cancer Res; 1999 Feb; 59(3):653-60. PubMed ID: 9973214
[TBL] [Abstract][Full Text] [Related]
14. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
16. [Paclitaxel (taxol)--a cytostatic drug with a new kind of mechanism of action].
Schalhorn B
Med Klin Suppl; 1993 Nov; 2():4-6. PubMed ID: 7904718
[No Abstract] [Full Text] [Related]
17. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
[TBL] [Abstract][Full Text] [Related]
18. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.
Zhou J; O'brate A; Zelnak A; Giannakakou P
Cancer Res; 2004 Dec; 64(23):8708-14. PubMed ID: 15574781
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
20. [Microtubules and antineoplastic drugs].
Arioka H; Saijo N
Gan To Kagaku Ryoho; 1994 Apr; 21(5):583-90. PubMed ID: 7908790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
